ESTRO 2024 - Abstract Book

S133 ESTRO 2024 the MDR may often demand more resources than the actual device development. However, with dedicated institutional procedures, the culture of innovation in radiotherapy can be preserved while living up to modern standards of operational safety and institutional responsibility. Invited Speaker

3563

AI for automation of brachytherapy planning

Anton Bouter

Centrum Wiskunde & Informatica, Evolutionary Intelligence, Amsterdam, Netherlands

Abstract:

Though automated treatment planning has been (clinically) available for many years, many challenges still remain. One of such challenges is the formulation of the optimization problem to be solved. Various recent approaches to automated treatment planning have approached this from a multi-objective, or multi-criterion, perspective, meaning that the treatment planning results in not only one plan, but a large set of plans, each having a different trade-off in terms of the optimization objectives. From this set of plans, a clinical expert can make an informed, patient-specific, decision on the selection of a treatment plan, ideally removing the need for manual adjustments during the treatment planning procedure. In this talk, I will discuss the basics of AI/optimization for automated treatment planning, and shortcomings of currently available options. Furthermore, I will go over some of the most promising automated treatment planning methods and their recent advancements, followed by a future perspective for AI for automated treatment planning.

3566

Beyond precision and tumour control: The Role of neurocognitive assessment in SRS/SRT/WBRT - A neuro oncologist's perspective

Andrea Pace

IRCCS Regina Elena Cancer Institute, Neurooncology, Rome, Italy

Abstract:

Cognitive deficits are common in people who have received cranial irradiation and may have a relevant impact on daily functioning and quality of life. Both the brain tumour itself and tumour treatment can cause cognitive deficits and patients with primary or metastatic brain tumours who receive radiotherapy have worse cognitive deficits than those who are radiotherapy naïve. Patients with primary or metastatic brain tumors who undergo radiotherapy exhibit cognitive impairments throughout the course of their disease. These impairments often include decline in memory, attention and executive function, and can be attributed to the tumor itself and/or side effects of its treatment. Recent studies identified neuroimaging correlates as biomarkers of cognitive decline including cortical atrophy and white matter abnormalities, showing association between cognitive deficits and gray and superficial with matter structures in the right medial temporal lobe.